

**For Immediate Release**

**Alembic Q3 Net Profit up 52% to Rs 131 Crores**

**Vadodara January 31<sup>st</sup>, 2018**

Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter ending 31<sup>st</sup> December 2017.

**Q3 FY18 Financial Highlights**

- Net Revenue up 8% to Rs 840 crores against Rs 777 crores last year.
- Net Profit at Rs 131 crores against Rs 86 crores last year.
- EBITDA margin at 22% against 19% last year

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “The Indian Branded business recovered showing a good growth. The US Generics business continues to do well as we pick up market share leading to higher volumes. Aleor, our Joint Venture for Dermatology products, filed its first ANDA.”

**Operational Highlights for the quarter**

**International Business**

- International Generics business revenue at Rs 311 crores against Rs 303 crores.
- US generics business revenue at Rs 237 crores against Rs 227 crores.
- 1 ANDA approval received during the quarter, 63 Cumulative ANDA approvals (70 with Orit acquisition).
- 4 ANDA filings during the quarter, Cumulative ANDA filings at 108 (119 with Orit acquisition).
- 2 new products launched in the US.
- R&D Spend at Rs 98 crores (12% of Net revenue) against Rs 121 crores (16% of Net revenue) last year.

**India Formulations Business**

- India formulations business for the quarter grew by 14% at Rs 349 crores as against Rs 307 crores last year. Though the numbers are not strictly comparable due to GST treatment.



**ALEMBIC PHARMACEUTICALS LIMITED**

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q3 FY18	Q3 FY17	% Change	9M FY18	9M FY17	% Change
International Generics	311	303	3%	854	964	-11%
India Formulations	349	307	14%	970	970	-
API	180	167	8%	453	459	-1%
<b>Total</b>	<b>840</b>	<b>777</b>	<b>8%</b>	<b>2277</b>	<b>2393</b>	<b>-5%</b>

The Profit break-up is as under:

(Rs in  
Crores)

Particulars	Q3 FY18	Q3 FY17	% Change	9M FY18	9M FY17	% Change
EBITDA	188	145	29%	468	480	-3%
EBITDA %	22%	19%		21%	20%	
Profit Before Tax	161	124	30%	400	417	-4%
Net Profit after Tax	131	86	52%	317	307	3%

#### About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.



#### **ALEMBIC PHARMACEUTICALS LIMITED**

Information about the company can be found at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com);  
(reuters: ALEM.NS) (bloomberg: ALPM) (nse: APLLTD) (bse: 533573)

For more information contact:

<b>Ajay Kumar Desai</b> Phone: +91 22 – 306 11681 Email: <a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a>	<b>Mitanshu Shah</b> Phone: +91 265 – 3007630 Email: <a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a>
---	---



**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123